Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciprofloxacin inhalation - Bayer/Novartis

Drug Profile

Ciprofloxacin inhalation - Bayer/Novartis

Alternative Names: Bay q 3939; BAYQ3939; Cipro DPI; Cipro inhale; Ciprofloxacin PulmoSphere®; Ciprofloxin inhalation powder programme

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare; Nektar Therapeutics
  • Developer Bayer HealthCare; Novartis
  • Class Anti-infectives; Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections; Bronchiectasis
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cystic fibrosis-associated respiratory tract infections; Pneumonia; Pseudomonal infections; Respiratory tract infections
  • Discontinued Bronchiectasis

Most Recent Events

  • 23 Sep 2021 Biomarkers information updated
  • 18 May 2018 Efficacy data from the phase III RESPIRE 1 and RESPIRE 2 trial in Bronchiectasis (Non-cystic fibrosis related) presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 03 Apr 2018 No recent reports of development identified - Phase-III for Pneumonia in Japan (Inhalation)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top